Effect of additional aprepitant on palonosetron and dexamethasone for prevention of moderately emetogenic chemotherapy-induced nausea and vomiting in patients with lung cancer: clinical phase II study

Effect of additional aprepitant on palonosetron and dexamethasone for prevention of moderately emetogenic chemotherapy-induced nausea and vomiting in patients with lung cancer: clinical phase II study - Effect of additional aprepitant on palonosetron and dexamethasone for prevention of moderately emetogenic chemotherapy-induced nausea and vomiting in patients with lung cancer: clinical phase II study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008318

Enrollment

Registered

2012-07-02

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Palonosetoron+Dexamethasone Palonosetoron+Aprepitant+Dexamethasone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)No prior chemotherapy 2)Patient receiving combination chemotherapy with CBDCA and moderately emetogenic anticancer drugs 7)Written IC.

Exclusion criteria

Exclusion criteria: 1)vomiting within 24h before first chemotherapy 2)continuatory use of severely or moderately emetogenic anticancer drugs after Day 2 3)concurrent radiotherapy 4) Severe complications 5)Symptomatic brain meta 6)Hypersensitivity for PaIonosetron, Aprepitant, Dexamethasone 7) Other patients who are unfit for the study as determined by the attending physician.

Design outcomes

Primary

Measure	Time frame
Complete Response (CR) rate	—

Countries

Japan

Contacts

Public ContactYoshiki Ishii

Dokkyo Medical University Department of Pulmonary Medicine and Clinical Immunology

ishiiysk@dokkyomed.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026